MARCIANO, ROBERTA
 Distribuzione geografica
Continente #
NA - Nord America 373
EU - Europa 264
AS - Asia 163
AF - Africa 18
Totale 818
Nazione #
US - Stati Uniti d'America 364
IT - Italia 152
SG - Singapore 58
CN - Cina 48
HK - Hong Kong 36
NL - Olanda 36
CI - Costa d'Avorio 18
IE - Irlanda 18
FI - Finlandia 12
SE - Svezia 11
FR - Francia 10
CA - Canada 9
DE - Germania 8
RU - Federazione Russa 8
IN - India 7
BE - Belgio 4
JO - Giordania 4
PK - Pakistan 4
GB - Regno Unito 3
IR - Iran 2
AZ - Azerbaigian 1
ES - Italia 1
IL - Israele 1
LT - Lituania 1
MM - Myanmar 1
UZ - Uzbekistan 1
Totale 818
Città #
Chandler 75
Singapore 48
Amsterdam 36
Hong Kong 36
Naples 34
Napoli 33
Santa Clara 30
Ashburn 29
Beijing 16
Millbury 15
Princeton 12
Nanchang 8
Ottawa 7
Boston 6
Des Moines 6
Hicksville 6
Munich 6
Nanjing 6
San Mateo 6
Caserta 5
Pune 5
Amman 4
Fucecchio 4
Lawrence 4
Seattle 4
Washington 4
Boardman 3
Casagiove 3
Falls Church 3
Formia 3
Hebei 3
Helsinki 3
Rome 3
Turin 3
Afragola 2
Ardabil 2
Changsha 2
Edegem 2
Prato 2
Redwood City 2
San Giorgio a Cremano 2
Shenyang 2
Toronto 2
Yellow Springs 2
Augusta 1
Baiano 1
Baku 1
Bangalore 1
Brussels 1
Casoria 1
Changchun 1
Changzhou 1
Falkenstein 1
Hefei 1
Islamabad 1
Jacksonville 1
Jiaxing 1
Kronberg 1
La Louvière 1
Lahore 1
Leawood 1
London 1
Marigliano 1
Milan 1
Montalbano Jonico 1
Montesilvano Marina 1
Mountain View 1
Nay Pyi Taw 1
Palermo 1
Paris 1
Paterno 1
Pizzo 1
Pomigliano d'Arco 1
Pozzuoli 1
Prineville 1
Rawalpindi 1
Redmond 1
San Giorgio A Cremano 1
San Jose 1
San Mango Piemonte 1
Sarno 1
Sesto Fiorentino 1
Shanghai 1
Tashkent 1
Tel Aviv 1
Wilmington 1
Totale 531
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 95
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 60
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 59
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 52
From biology to therapy: Improvements of therapeutic options in Lung cancer 51
Mechanisms of resistance to mTOR inhibitors 51
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 50
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 49
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 49
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 47
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 46
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 45
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 41
Correlation between bevacizumab-related hypertension and response in mCRC patients 36
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 35
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 33
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial 28
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer 28
Totale 855
Categoria #
all - tutte 3.920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.920


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202026 0 0 0 0 0 0 0 1 1 5 16 3
2020/202153 2 0 4 0 6 6 1 5 12 3 13 1
2021/2022126 1 0 4 10 0 4 2 4 20 10 36 35
2022/2023204 22 12 6 7 26 28 3 23 23 38 11 5
2023/2024141 4 18 23 13 6 24 1 23 0 0 19 10
2024/2025176 21 19 6 11 23 46 50 0 0 0 0 0
Totale 855